Nathan Rice

Stock Analyst at Piper Sandler

(2.88)
# 1,552
Out of 5,127 analysts
60
Total ratings
50%
Success rate
8.57%
Average return

Stocks Rated by Nathan Rice

First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $40.10
Upside: +19.72%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $35.85
Upside: +17.15%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $30.35
Upside: +15.32%
Bank First
Oct 23, 2025
Maintains: Neutral
Price Target: $137$142
Current: $125.44
Upside: +13.20%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $80.60
Upside: -8.19%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $127.30
Upside: -34.01%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $170.58
Upside: +15.49%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $23.24
Upside: -61.27%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $712.39
Upside: -38.94%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $283.91
Upside: -17.93%
Initiates: Neutral
Price Target: $83
Current: $46.92
Upside: +76.90%
Initiates: Overweight
Price Target: $15
Current: $20.27
Upside: -26.00%